Halozyme, Skye Bioscience team on subcutaneous obesity therapy

Halozyme Therapeutics, a San Diego-based drug delivery company, said it has entered into a non-exclusive global collaboration and license agreement with Skye Bioscience to support development of a subcutaneous formulation of the investigational antibody nimacimab for obesity treatment.

Under the collaboration, Skye has licensed Halozyme’s drug delivery technology to enable evaluation of higher subcutaneous doses of nimacimab through delivery of larger injection volumes, according to the companies. The approach is intended to support dose-ranging strategies that may not be feasible using conventional subcutaneous delivery methods.

Halozyme said the agreement expands the application of its delivery technology into the obesity market, while Skye stated that the collaboration will enable it to evaluate nimacimab both as a standalone therapy and in combination with GLP-1 receptor agonists.

Skye will make milestone payments tied to specified development and commercialization events, according to the companies. Halozyme is also eligible to receive mid-single-digit royalties on net sales of nimacimab products developed under the agreement for at least 10 years, the companies said.

According to the announcement, Skye plans to initiate a Phase IIb clinical trial of nimacimab formulated with the licensed delivery technology in obesity in mid-2026. The study is expected to evaluate both monotherapy and combination treatment with a GLP-1 receptor agonist.